Huatai (06886) completes the issuance of 2.6 billion yuan subordinated bonds.
Huatai Securities (06886) issued a notice stating that according to the "Huatai Securities Limited Company 2025 Targeting Professional Investors...
Huatai (06886) announced that according to the "Announcement on the Public Offering of Subordinated Bonds (Fifth Tranche) of Huatai Co., Ltd. to Professional Investors in 2025", the subordinated bonds (Fifth Tranche) to be issued by Huatai Co., Ltd. to professional investors in 2025 are divided into two types, with a maturity of 3 years for Type One and 5 years for Type Two.
The bonds introduce a call option between types, with no restriction on the call ratio. The company will decide whether to exercise the call option between types based on the subscription situation within the issuance size, but the total issuance size of both types combined will not exceed 5 billion yuan (including 5 billion yuan). The issuance price of the bonds is 100 yuan per unit, and they will be issued publicly to professional institutional investors.
The issuance of the bonds ended on November 11, 2025. The final issuance size for Type One is 1.5 billion yuan, with a coupon rate of 2.03% and a subscription multiple of 3.07 times; the issuance size for Type Two is 1.1 billion yuan, with a coupon rate of 2.20% and a subscription multiple of 2.94 times.
Related Articles
Crown Advanced Material (688560.SH) terminates investment agreement with CECEP Solar Energy for backsheet and functional film production base project.

Guangdong Zhongsheng Pharmaceutical (002317.SZ): The innovative drug Arlaidevir project has received top-line analysis data results from two Phase III clinical trials.

New stock news | Luku Technology submits application to the Hong Kong Stock Exchange, the shipment volume of vein smart locks in 2024 ranks first in the world.
Crown Advanced Material (688560.SH) terminates investment agreement with CECEP Solar Energy for backsheet and functional film production base project.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): The innovative drug Arlaidevir project has received top-line analysis data results from two Phase III clinical trials.

New stock news | Luku Technology submits application to the Hong Kong Stock Exchange, the shipment volume of vein smart locks in 2024 ranks first in the world.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


